Molecular Endocrinology, Vol 6, 2071-2078, Copyright © 1992 by Endocrine Society

ARTICLES

Switching agonistic, antagonistic, and mixed transcriptional responses to 11 beta-substituted progestins by mutation of the progesterone receptor

T Garcia, B Benhamou, D Gofflo, A Vergezac, D Philibert, P Chambon and H Gronemeyer
Laboratoire de Genetique Moleculaire des Eucaryotes du CNRS, Faculte de Medecine, Strasbourg, France.

The study of transcription activation by a series of RU486-related 11 beta-substituted progestins revealed three types of ligands: agonists, antagonists, and a novel type of compounds that exerted a mixed activity. These ligands conferred to the human progesterone receptor (hPR) only weak activation properties despite high affinity binding and, hence, acted as agonists and, at the same time, as partial antagonists of pure agonists. When the same series of ligands was tested with mutant PRs, transcriptional activation/inactivation profiles were different from those seen with the wild-type PR, since several steroids initially classified as antagonists switched to mixed responses. One compound that acted as an antagonist for the hPR was an agonist for a mutated PR in which 15 amino acids of the hormone-binding domain were replaced by the corresponding divergent residues of the chicken homolog. In analyzing a series of steroids with wild-type and mutant PRs, we observed that a phenyl group (or a phenyl derivative) in the 11 beta position of RU486-related steroids generates antagonism with hPR, but has to be bound in a critical position in the hormone- binding domain to exert its antagonistic activity. Apparently, a deviation from this positioning by mutations in the hormone-binding domain can generate mixed or even agonistic activities.

This article has been cited by other articles:

				D. Masiello, S.-Y. Chen, Y. Xu, M. C. Verhoeven, E. Choi, A. N. Hollenberg, and S. P. Balk Recruitment of {beta}-Catenin by Wild-Type or Mutant Androgen Receptors Correlates with Ligand-Stimulated Growth of Prostate Cancer Cells Mol. Endocrinol., October 1, 2004; 18(10): 2388 - 2401. [Abstract] [Full Text] [PDF]

				V. S. Wilson, K. Bobseine, C. R. Lambright, and L. E. Gray Jr. A Novel Cell Line, MDA-kb2, That Stably Expresses an Androgen- and Glucocorticoid-Responsive Reporter for the Detection of Hormone Receptor Agonists and Antagonists Toxicol. Sci., March 1, 2002; 66(1): 69 - 81. [Abstract] [Full Text] [PDF]

				R. N. Taylor, J.-F. Savouret, C. Vaisse, J.-L. Vigne, I. Ryan, D. Hornung, M. Seppälä, and E. Milgrom Promegestone (R5020) and Mifepristone (RU486) Both Function as Progestational Agonists of Human Glycodelin Gene Expression in Isolated Human Epithelial Cells J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4006 - 4012. [Abstract] [Full Text]

				E. K. Gass, S. A. Leonhardt, S. K. Nordeen, and D. P. Edwards The Antagonists RU486 and ZK98299 Stimulate Progesterone Receptor Binding to Deoxyribonucleic Acid in Vitro and in Vivo, but Have Distinct Effects on Receptor Conformation Endocrinology, April 1, 1998; 139(4): 1905 - 1919. [Abstract] [Full Text] [PDF]

				K. Ekena, J. A. Katzenellenbogen, and B. S. Katzenellenbogen Determinants of Ligand Specificity of Estrogen Receptor-alpha : Estrogen versus Androgen Discrimination J. Biol. Chem., January 9, 1998; 273(2): 693 - 699. [Abstract] [Full Text] [PDF]

				B. M. Vayssière, S. Dupont, A. Choquart, F. Petit, T. Garcia, C. Marchandeau, H. Gronemeyer, and M. Resche-Rigon Synthetic Glucocorticoids That Dissociate Transactivation and AP-1 Transrepression Exhibit Antiinflammatory Activity in Vivo Mol. Endocrinol., August 1, 1997; 11(9): 1245 - 1255. [Abstract] [Full Text]

				C.-i. Wong, W. R. Kelce, M. Sar, and E. M. Wilson Androgen Receptor Antagonist versus Agonist Activities of the Fungicide Vinclozolin Relative to Hydroxyflutamide J. Biol. Chem., August 25, 1995; 270(34): 19998 - 20003. [Abstract] [Full Text] [PDF]